1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
2
|
Tang ZY, Ye SL, Liu YK, et al: A decade’s
studies on metastasis of hepatocellular carcinoma. J Cancer Res
Clin Oncol. 130:187–196. 2004.
|
3
|
Padhya KT, Marrero JA and Singal AG:
Recent advances in the treatment of hepatocellular carcinoma. Curr
Opin Gastroenterol. 29:285–292. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Sankari SL, Masthan KM, Babu NA, et al:
Apoptosis in cancer - an update. Asian Pac J Cancer Prev.
13:4873–4878. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Wu J, Hu D and Zhang R: Depletion of Bmi-1
enhances 5-fluorouracil-induced apoptosis and autophagy in
hepatocellular carcinoma cells. Oncol Lett. 4:723–726.
2012.PubMed/NCBI
|
6
|
Wang H and Cho CH: Effect of NF-κB
signaling on apoptosis in chronic inflammation-associated
carcinogenesis. Curr Cancer Drug Targets. 10:593–599. 2010.
|
7
|
Gocho T, Uwagawa T, Furukawa K, et al:
Combination chemotherapy of serine protease inhibitor nafamostat
mesilate with oxaliplatin targeting NF-κB activation for pancreatic
cancer. Cancer Lett. 333:89–95. 2013.PubMed/NCBI
|
8
|
Monks NR, Biswas DK and Pardee AB:
Blocking anti-apoptosis as a strategy for cancer chemotherapy:
NF-κB as a target. J Cell Biochem. 92:646–650. 2004.PubMed/NCBI
|
9
|
Teo H, Ghosh S, Luesch H, et al:
Telomere-independent Rap1 is an IKK adaptor and regulates
NF-κB-dependent gene expression. Nat Cell Biol. 12:758–767.
2010.PubMed/NCBI
|
10
|
Kaseb AO, Shindoh J, Patt YZ, et al:
Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil
(PIAF)chemotherapy in patients with no hepatitis or cirrhosis is
associated with improved response rate, resectability, and survival
of initially unresectable hepatocellular carcinoma. Cancer.
119:3334–3342. 2013.
|
11
|
Yamashita T: Current status of
hepatocellular carcinoma treatment in Japan: hepatic arterial
infusion chemotherapy. Clin Drug Investig. 32(Suppl 2): 15–23.
2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Spallarossa P, Altieri P, Aloi C, et al:
Doxorubicin induces senescence or apoptosis in rat neonatal
cardiomyocytes by regulating the expression levels of the telomere
binding factors 1 and 2. Am J Physiol Heart Circ Physiol.
297:H2169–H2181. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Kato M, Nakayama M, Agata M, et al: Gene
expression levels of human shelterin complex and
shelterin-associated factors regulated by the topoisomerase II
inhibitors doxorubicin and etoposide in human cultured cells.
Tumour Biol. 34:723–733. 2013. View Article : Google Scholar
|
14
|
Biroccio A, Rizzo A, Elli R, et al: TRF2
inhibition triggers apoptosis and reduces tumourigenicity of human
melanoma cells. Eur J Cancer. 42:1881–1888. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Oh BK, Jo Chae K, Park C, et al: Telomere
shortening and telomerase reactivation in dysplastic nodules of
human hepatocarcinogenesis. J Hepatol. 39:786–792. 2003. View Article : Google Scholar : PubMed/NCBI
|
16
|
Oh BK, Kim YJ, Park C, et al:
Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is
related to telomere shortening during human multistep
hepatocarcinogenesis. Am J Pathol. 166:73–80. 2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
O’Connor MS, Safari A, Liu D, et al: The
human Rap1 protein complex and modulation of telomere length. J
Biol Chem. 279:28585–28591. 2004.PubMed/NCBI
|
18
|
Hayden MS and Ghosh S: Shared principles
in NF-κB signaling. Cell. 132:344–362. 2008.
|
19
|
Körber MI, Klingenbrunner S, Bartsch R, et
al: NF-κB addiction and resistance to 5-fluorouracil in a
multi-stage colon carcinoma model. Int J Clin Pharmacol Ther.
51:35–37. 2013.
|
20
|
Zhang H, Ozaki I, Hamajima H, et al:
Vitamin K2 augments 5-fluorouracil-induced growth inhibition of
human hepatocellular carcinoma cells by inhibiting NF-κB
activation. Oncol Rep. 25:159–166. 2011.PubMed/NCBI
|
21
|
Cheng Q, Lee HH, Li Y, et al: Upregulation
of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance,
which can be overcome by NF-κB inhibition. Oncogene. 19:4936–4940.
2000.PubMed/NCBI
|